Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New registry tracks YORVIPATH in pregnancy to assess safety for mom and baby

NCT ID NCT07345494

First seen Jan 19, 2026 · Last updated May 25, 2026 · Updated 13 times

Summary

This study is a pregnancy registry that collects information from women who took YORVIPATH for hypoparathyroidism around the time of pregnancy or while breastfeeding. Researchers will follow about 50 women and their babies for at least a year to watch for complications, birth defects, and developmental milestones. The goal is to better understand the risks and safety of this medication during pregnancy and breastfeeding.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HYPOPARATHYROIDISM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Ascendis Investigational Site

    RECRUITING

    Morgantown, West Virginia, 26508, United States

Conditions

Explore the condition pages connected to this study.